LOBEF - Lobe Sciences buys Altemia & Company

2023-04-18 09:55:55 ET

• Lobe Sciences ( OTCQB:LOBEF ) to acquire a 100% interest in Altemia & Company, which includes all assets, know-how, intellectual property and commercial inventory of the seller to manage patients suffering from Sickle Cell Disease.
• The seller has no current or long-term liabilities.
• Mr. Philip J. Young, Chairman and CEO, "This transaction will transform our company into a revenue generating biotech company committed to treating Orphan Diseases and separating Lobe from the myriad of clinical stage companies in North America and Europe. We will be able to use the revenue from the SCD sales to fund ongoing and planned clinical activities with L-130 and L-131. I look forward to providing updates as we move forward with the planning and launch of Altemia for the treatment of Sickle Cell Disease."

For further details see: